INTUNIV XR is the first ever and only ADHD treatment approved by Health
Canada for use both alone or in addition to stimulants
MONTREAL, Nov. 20, 2013 /CNW Telbec/ - Canadian families now have a new
option to help manage their child's Attention Deficit Hyperactivity
Disorder (ADHD); INTUNIV XR (guanfacine hydrochloride extended release
tablets), a new and different class of ADHD medication, is now
available in Canada for the treatment of ADHD in children ages 6 to 12.1 The new once-daily treatment is approved for use either as a
stand-alone treatment for ADHD or in addition to stimulants for
children not responding optimally to stimulants.1
"ADHD is a neurobiological disorder that can result in significant
impairment to learning and other distressing symptoms when not
well-controlled, often causing stress and suffering for the whole
family," said Heidi Bernhardt, President and Executive Director, Centre
for ADHD Awareness Canada (CADDAC). "The more options we have to treat
children with ADHD the better chance we have of finding the best
combination of treatments for all children struggling with this
Between 230,000 to 550,000 Canadian children have ADHD.2,3 In a recent survey of 311 parents of children with ADHD, more than half
stated that their child is not well controlled on current medication.
Almost one in ten (8 per cent) reported their child is not controlled,
and a further 44 per cent stated their child is only partially
controlled,4 suggesting many children may not be receiving the best possible care to
manage their ADHD symptoms.
"Stimulants are the go-to treatment option for ADHD as they successfully
manage the symptoms of most children, but not all respond as well as
hoped." says Dr. Kenny Handelman, psychiatrist at the Oakville
Trafalgar Memorial Hospital and expert in ADHD. "INTUNIV XR works
differently than all other approved ADHD treatments. What's more, it
can be used as a stand-alone treatment, or in combination with
stimulant medication - opening the door to new choices for children
still struggling with their ADHD."
INTUNIV XR is a selective alpha2A-adrenergic receptor agonist, providing an alternative treatment for
children (6 to 12 years old) in whom response to stimulant therapy has
About INTUNIV XR
INTUNIV XR (guanfacine hydrochloride extended-release tablets) is an
oral, once-daily treatment for Attention Deficit Hyperactivity Disorder
(ADHD). Its active ingredient, guanfacine, is a selective alpha2A-adrenergic receptor agonist.
INTUNIV XR received Health Canada approval 1) as monotherapy for the
treatment of ADHD in children aged 6 to 12 years, and 2) as adjunctive
therapy to psychostimulants for the treatment of ADHD in children, aged
6 to 12 years, with a sub-optimal response to psychostimulants.
The efficacy of INTUNIV XR in the treatment of ADHD was established in
two, placebo-controlled monotherapy pivotal trials. A third study
further evaluated the safety and efficacy of INTUNIV XR as adjunctive
therapy to psychostimulants.
For more information regarding INTUNIV XR, please consult the product
monograph available here: http://shirecanada.com/en/shire-canada/PDF%202013/Intuniv_XR_PM%2005-Jul-2013%20(2).pdf.
Attention Deficit Hyperactivity Disorder (ADHD) is a neurobiological
disorder that affects approximately 5 to 12 per cent of the
population.2 The most common behaviors exhibited by those who have ADHD
are inattention, hyperactivity, and impulsivity. People with ADHD often
have difficulty focusing, are easily distracted, have trouble staying
still, and frequently are unable to control their impulsive behavior.
If left unmanaged, ADHD can have serious adverse effects on the lives
of those affected. Although there is no cure for ADHD, there are
accepted treatments that specifically target its symptoms. Standard
treatments include educational approaches, medication as well as
psychological or behavioral therapy.
Shire enables people with life-altering conditions to lead better lives.
Our strategy is to focus on developing and marketing innovative
specialty medicines to meet significant unmet patient needs.
We provide treatments in Neuroscience, Rare Diseases, Gastrointestinal,
Internal Medicine and Regenerative Medicine and we are developing
treatments for symptomatic conditions treated by specialist physicians
in other targeted therapeutic areas.
About Shire Canada Inc.
Shire Canada Inc. is a subsidiary of Shire with headquarters located in
Montréal (Saint-Laurent), Québec. For more information, please visit: www.shirecanada.com.
1 INTUNIV XR Product Monograph, Shire Canada Inc., July 5, 2013.
2 Canadian ADHD Resource Alliance. What is ADHD? http://caddra.ca/cms4/index.php?option=com_content&view=article&id=22&Itemid=233&lang=en Accessed July 31, 2013.
3 Statistics Canada. Census families by number of children at home, by
province and territory http://www.statcan.gc.ca/tables-tableaux/sum-som/l01/cst01/famil50a-eng.htm
4 IPSOS ADHD Parent Poll. (Sponsored by Shire). August 2013
Image with caption: "Shire Logo (CNW Group/Shire)". Image available at: http://photos.newswire.ca/images/download/20131120_C9023_PHOTO_EN_33585.jpg
For further information:
NATIONAL Public Relations